Hancock Whitney Corp Has $767,000 Holdings in Elevance Health, Inc. (NYSE:ELV)

Hancock Whitney Corp trimmed its stake in shares of Elevance Health, Inc. (NYSE:ELV) by 17.1% during the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 2,080 shares of the company’s stock after selling 429 shares during the period. Hancock Whitney Corp’s holdings in Elevance Health were worth $767,000 as of its most recent SEC filing.

Several other institutional investors have also added to or reduced their stakes in the stock. Flagship Wealth Advisors LLC acquired a new stake in shares of Elevance Health in the 4th quarter valued at approximately $26,000. OFI Invest Asset Management bought a new position in shares of Elevance Health in the 4th quarter valued at about $29,000. WealthTrak Capital Management LLC acquired a new position in shares of Elevance Health during the 4th quarter worth about $29,000. Lee Danner & Bass Inc. bought a new stake in shares of Elevance Health in the 4th quarter valued at about $30,000. Finally, Crews Bank & Trust acquired a new stake in Elevance Health in the 4th quarter valued at about $34,000. 89.24% of the stock is owned by institutional investors.

Insider Buying and Selling at Elevance Health

In other Elevance Health news, CFO Mark Kaye sold 4,588 shares of the business’s stock in a transaction dated Thursday, April 24th. The shares were sold at an average price of $424.82, for a total value of $1,949,074.16. Following the transaction, the chief financial officer now directly owns 18,977 shares in the company, valued at $8,061,809.14. The trade was a 19.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CAO Ronald W. Penczek sold 443 shares of the firm’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $415.13, for a total transaction of $183,902.59. Following the sale, the chief accounting officer now owns 1,847 shares of the company’s stock, valued at approximately $766,745.11. The trade was a 19.34 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 8,535 shares of company stock worth $3,521,612 in the last quarter. 0.29% of the stock is currently owned by company insiders.

Analysts Set New Price Targets

A number of research firms recently weighed in on ELV. Guggenheim restated a “buy” rating and issued a $518.00 price target on shares of Elevance Health in a research note on Wednesday. Sanford C. Bernstein restated an “outperform” rating on shares of Elevance Health in a research note on Friday, March 28th. Argus upgraded shares of Elevance Health from a “hold” rating to a “buy” rating and set a $450.00 price target on the stock in a research note on Monday, March 17th. Mizuho raised their price objective on shares of Elevance Health from $455.00 to $505.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 9th. Finally, Wells Fargo & Company decreased their target price on Elevance Health from $483.00 to $478.00 and set an “overweight” rating on the stock in a research report on Tuesday, January 28th. Four equities research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $509.44.

Elevance Health Price Performance

ELV opened at $421.55 on Friday. The firm’s fifty day moving average price is $420.00 and its two-hundred day moving average price is $408.48. The company has a market capitalization of $95.43 billion, a price-to-earnings ratio of 16.46, a P/E/G ratio of 1.18 and a beta of 0.77. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.45 and a quick ratio of 1.50. Elevance Health, Inc. has a 1 year low of $362.21 and a 1 year high of $567.26.

Elevance Health (NYSE:ELV) last issued its quarterly earnings data on Tuesday, April 22nd. The company reported $11.97 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $10.60 by $1.37. Elevance Health had a net margin of 3.38% and a return on equity of 18.28%. The business had revenue of $48.77 billion during the quarter, compared to the consensus estimate of $46.26 billion. As a group, analysts anticipate that Elevance Health, Inc. will post 33.96 earnings per share for the current fiscal year.

Elevance Health Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, June 25th. Shareholders of record on Tuesday, June 10th will be given a $1.71 dividend. The ex-dividend date is Tuesday, June 10th. This represents a $6.84 annualized dividend and a yield of 1.62%. Elevance Health’s dividend payout ratio is currently 26.71%.

About Elevance Health

Elevance Health, Inc, together with its subsidiaries, operates as a health benefits company in the United States. The company operates through four segments: Health Benefits, CarelonRx, Carelon Services, and Corporate & Other. It offers a variety of health plans and services to program members; health products; an array of fee-based administrative managed care services; and specialty and other insurance products and services, such as stop loss, dental, vision, life, disability, and supplemental health insurance benefits.